1. 776TiPPACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. (18th September 2017) Authors: Chen, I.; Johansen, J.S.; Zimmers, T.A.; Dehlendorff, C.; Kirk Parner, V.; Vittrup Jensen, B.; Nielsen, D. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗